Fonseca Marcos M, Mocelin Faberson João, Grill Marcelo Halfen, Gianesini Sergio, Miyake Kasuo, Argenta Rodrigo, Pereira Adamastor H
28124Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Clínica Prime Vascular, Porto Alegre, RS, Brazil.
Phlebology. 2023 Apr;38(3):165-171. doi: 10.1177/02683555231153533. Epub 2023 Jan 19.
Cryo-Laser & Cryo-Sclerotherapy (CLaCS) is a technique which combines thermal sclerotherapy and injection sclerotherapy. Telangiectasias and small varicosities are targeted by a transdermal laser and right after receive injection sclerotherapy. A cooling device blows -20°C air onto the skin and needle in a pre-, parallel-, and post-fashion.
Our objective was to establish if there is a difference in result and complications by varying the sclerosing agent but keeping the same ND:Yag long pulse laser parameters in the treatment of small varicosities.
Fifty five patients were enrolled prospectively and randomized to two groups; in the group 1 dextrose 75% was the sclerosing agent used in combination with the ND:Yag long pulse laser and, in the group 2, the same laser technique was used but the sclerosing agent was polidocanol 0.3% and dextrose 67%.
The results were evaluated 30 days after the treatment by the patients and for blinded evaluators using before and after standardized photos with and without augmented reality. In the patient's perspective and in the blinded evaluation of the regular photos, no differences between the groups were found. Both groups had low rates of hyperpigmentation and bruising with no statistical difference. Patients treated with polidocanol had less pain after the treatment and a better clearance rate in the photos with augmented reality. No major complications were found.
The treatment of small varicosities with CLaCS using Dextrose 75% or polidocanol 0.3% and Dextrose 67.5% is a safe and effective procedure and both sclerosing agents can be used with similar results. Possibly, in the polidocanol group more nonvisible reticular veins were cleared, but the implication of this find is not clear.
冷冻激光与冷冻硬化疗法(CLaCS)是一种将热硬化疗法和注射硬化疗法相结合的技术。通过经皮激光靶向治疗毛细血管扩张和小静脉曲张,随后立即进行注射硬化疗法。一种冷却装置以治疗前、治疗中和治疗后的方式将-20°C的空气吹向皮肤和针头。
我们的目的是确定在治疗小静脉曲张时,在保持相同的钕:钇铝石榴石长脉冲激光参数的情况下,改变硬化剂是否会导致结果和并发症的差异。
前瞻性纳入55例患者并随机分为两组;第1组使用75%葡萄糖作为硬化剂与钕:钇铝石榴石长脉冲激光联合使用,第2组使用相同的激光技术,但硬化剂为0.3%聚多卡醇和67%葡萄糖。
治疗30天后,由患者和不知情的评估者使用标准化的治疗前后照片(有无增强现实)对结果进行评估。从患者的角度以及对普通照片的不知情评估来看,两组之间未发现差异。两组的色素沉着和瘀伤发生率均较低,无统计学差异。使用聚多卡醇治疗的患者治疗后疼痛较轻,在增强现实照片中的清除率更高。未发现重大并发症。
使用75%葡萄糖或0.3%聚多卡醇和67.5%葡萄糖的CLaCS治疗小静脉曲张是一种安全有效的方法,两种硬化剂的使用效果相似。可能在聚多卡醇组中清除了更多不可见的网状静脉,但这一发现的意义尚不清楚。